Home

Driv – Center for Research on Women’s Health

Main content

Driv - Center for women`s health research

Driv gathers and strengthens research on women's health through collaboration between the university, primary healthcare services, and specialist healthcare services. Read more about the partners at Driv here.

The center is built on outstanding research environments among the partners in biomedical and translational research, clinical research, and public health research. For us, women's health encompasses a wide range of issues, including diseases that exclusively affect women, diseases that more frequently affect women than men, and diseases that manifest differently in women compared to men.

Driv's goal is to promote research that contributes to eliminating gender-based disparities in healthcare. We aim for women's health to receive the same understanding, prioritization, and treatment as other health areas, ensuring that no aspects of women's health are overlooked or undervalued.

 

Position paper on women's health
header photo

A Call for Stronger EU Focus on Women’s Health Research

DRIV – UiB’s Center for Research on Women’s Health urges the EU to strengthen women’s health research in Europe. In this position paper, UiB highlights the need for increased funding, dedicated partnerships, and policy measures to close critical knowledge gaps in women’s health.

News
TMF Women's Health Researchers

Major Investment in Women's Health Research

Four new research projects in women's health are now being launched, supported by a comprehensive initiative from the Trond Mohn Research Foundation, the University of Bergen, and Helse Bergen. The projects include research on ovarian cancer, mutations that occur in fetal development, early...

News
Line Bjørge

Important article about immunotherapy and survival in ovarian cancer

In a recently published study from CCBIO and Helse Bergen HF, Luka Tandaric, Line Bjørge, and her research group have investigated how immunotherapy with two specific drugs – oleclumab (anti-CD73) and durvalumab (anti-PD-L1) – affects immune cells in the blood of patients with ovarian cancer during...

News
Hjelmeland et al

New biomarker can predict cancer prognosis and spread

Martha E. Hjelmeland, Jone Trovik and Camilla Krakstad are three of the researchers at the Women's Clinic at Haukeland University Hospital and the Bergen Research Group for Gynecological Cancer, who have discovered that the loss of vimentin, a protein, in preoperative biopsies can predict poor...